Acer Therapeutics Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Acer Therapeutics stock.
View analyst ratings for Acer Therapeutics or view top-rated stocks.

Wall Street analysts have given Acer Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Acer Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Acer Therapeutics saw a decrease in short interest in the month of February. As of February 12th, there was short interest totaling 126,100 shares, a decrease of 52.6% from the January 28th total of 265,900 shares. Based on an average trading volume of 818,100 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.3% of the shares of the stock are short sold.
View Acer Therapeutics' Short Interest.

Acer Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Acer Therapeutics.

Acer Therapeutics Inc. (NASDAQ:ACER) released its quarterly earnings data on Sunday, February, 28th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.09.
View Acer Therapeutics' earnings history.

Acer Therapeutics' stock was trading at $3.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ACER stock has decreased by 15.7% and is now trading at $2.85.
View which stocks have been most impacted by COVID-19.

3 brokers have issued 1 year price objectives for Acer Therapeutics' shares. Their forecasts range from $10.00 to $10.00. On average, they expect Acer Therapeutics' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 250.9% from the stock's current price.
View analysts' price targets for Acer Therapeutics or view top-rated stocks among Wall Street analysts.

64 employees have rated Acer Therapeutics CEO Jason Chen on Glassdoor.com. Jason Chen has an approval rating of 99% among Acer Therapeutics' employees. This puts Jason Chen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Acer Therapeutics include DiaMedica Therapeutics (DMAC), ObsEva (OBSV), Lantern Pharma (LTRN), Palatin Technologies (PTN), Corbus Pharmaceuticals (CRBP), Clearside Biomedical (CLSD), AcelRx Pharmaceuticals (ACRX), Atossa Therapeutics (ATOS), OncoSec Medical (ONCS), Aptevo Therapeutics (APVO), Adamas Pharmaceuticals (ADMS), Hepion Pharmaceuticals (HEPA), Eyenovia (EYEN), Seelos Therapeutics (SEEL) and GlycoMimetics (GLYC).
View all of ACER's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), Amarin (AMRN), VBI Vaccines (VBIV), NVIDIA (NVDA), Idera Pharmaceuticals (IDRA) and Inovio Pharmaceuticals (INO).

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

Acer Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (0.93%) and HighPoint Advisor Group LLC (0.24%). Company insiders that own Acer Therapeutics stock include Chris Schelling, Donald Joseph and Steve Aselage.
View institutional ownership trends for Acer Therapeutics.

ACER stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc..
View insider buying and selling activity for Acer Therapeutics or view top insider-selling stocks.

ACER stock was acquired by a variety of institutional investors in the last quarter, including HighPoint Advisor Group LLC. Company insiders that have bought Acer Therapeutics stock in the last two years include Chris Schelling, Donald Joseph, and Steve Aselage.
View insider buying and selling activity for Acer Therapeutics or or view top insider-buying stocks.

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACER stock can currently be purchased for approximately $2.85.

Acer Therapeutics has a market capitalization of $40.78 million. The biopharmaceutical company earns $-29,420,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis.

Acer Therapeutics employs 20 workers across the globe.

The official website for Acer Therapeutics is www.acertx.com.

Acer Therapeutics is headquartered at 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458.

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]